Stockscreener 앱 받기
25.27
1.48%
-0.38
시간 외 거래:
25.40
0.13
+0.51%
전일 마감가:
$25.65
열려 있는:
$25.68
하루 거래량:
590.09K
Relative Volume:
0.43
시가총액:
$2.23B
수익:
-
순이익/손실:
$-151.78M
주가수익비율:
-12.27
EPS:
-2.0595
순현금흐름:
$-136.42M
1주 성능:
-2.99%
1개월 성능:
-5.39%
6개월 성능:
-15.65%
1년 성능:
+69.77%
1일 변동 폭
$24.95
$25.86
1주일 범위
$24.95
$27.75
52주 변동 폭
$14.53
$47.65
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER RD., RADNOR
Compare MLYS vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
25.27 | 2.28B | 0 | -151.78M | -136.42M | -2.0595 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-27 | 개시 | TD Cowen | Buy |
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys (NASDAQ: MLYS) insider plans sale after $2,696,321.98 June stock deal - Stock Titan
Mineralys Plunges As Costly Royalty Deal Shocks Wall Street - TipRanks
People on the Move: Jessica Wagner Keliher, SPHR, Joins Mineralys Therapeutics as Vice President, Talent Management - BioBuzz
Timothy G. Youngquist 2020 Irrevocable Trust Takes $2.72 Million Position in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (MLYS) Q2 2026 Earnings Call Transcript - AOL.com
Mineralys Builds $661 Million War Chest Ahead of FDA Decision - MyChesCo
Mineralys Grants Equity Awards to New Medical Chief - MyChesCo
TimesSquare Capital Management LLC Invests $6.36 Million in Mineralys Therapeutics, Inc. $MLYS - MarketBeat
Mineralys (NASDAQ: MLYS) insider adds 417-share sale to six-figure run - Stock Titan
Mineralys Therapeutics, Inc. $MLYS Shares Bought by Bank of America Corp DE - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Downgraded by Zacks Research to "Strong Sell" - MarketBeat
Mineralys Therapeutics (NASDAQ:MLYS) Cut to "Strong Sell" at Wall Street Zen - MarketBeat
Q3 EPS Estimate for Mineralys Therapeutics Raised by Analyst - MarketBeat
Mineralys Therapeutics (NASDAQ: MLYS) insider files Form 144 to sell 14,056 shares - Stock Titan
Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $40 to $56 - Moomoo
What is HC Wainwright's Estimate for MLYS FY2030 Earnings? - MarketBeat
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $55 - Moomoo
BofA Securities Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $49 - Moomoo
Mineralys' New Chief Medical Officer Receives 4-Year Equity Awards - Stock Titan
How Investors May Respond To Mineralys Therapeutics (MLYS) Wider Q2 Loss, Lorundrostat PDUFA Date And Royalty Buyback - webull.com
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock - Investing.com
Mineralys Therapeutics CMO David Rodman sells $58,785 in stock By Investing.com - Investing.com Australia
Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $58,785.30 in Stock - MarketBeat
Mineralys Therapeutics (MLYS) CMO exercises options, sells 2,170 shares under plan - Stock Titan
Mineralys Therapeutics (NASDAQ:MLYS) Shares Gap Down After Earnings Miss - MarketBeat
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.5, Implies 77% Upside - TradingView
Mineralys Therapeutics, Inc. Stock 12‑Month Price Target Cut to $48.75, Implies 78% Upside - TradingView
Transcript : Mineralys Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... By GuruFocus - Investing.com Canada
Mineralys Therapeutics Inc (MLYS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ... - Yahoo Finance UK
Mineralys Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Mineralys Q2 Results: Net Loss Widens To $241.1 Million - scanx.trade
Mineralys Therapeutics Q2 Earnings Call Highlights - MarketBeat
MLYS: Q2 2026 featured robust launch preparations, strategic capital moves, and strong lorundrostat data - TradingView
Mineralys Therapeutics (NASDAQ:MLYS) Announces Earnings Results - MarketBeat
Earnings call transcript: Mineralys Q2 2026 loss widens, shares fall after hours - Investing.com
How Mineralys Therapeutics Inc. (MLYS) Affects Rotational Strategy Timing - Stock Traders Daily
Why is Mineralys Therapeutics stock sliding today? - Investing.com
Why is Mineralys Therapeutics stock sliding today? By Investing.com - Investing.com Canada
Mineralys Therapeutics, Inc. Q2 2026: Net loss $(241.1)M, EPS $(2.85) — 10-Q Summary - TradingView
Mineralys Therapeutics (NASDAQ: MLYS) widens loss but builds $661M cash war chest - Stock Titan
Mineralys Therapeutics Q2 Loss Widens - marketscreener.com
MINERALYS THERAPEUTICS ($MLYS) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings Flash (MLYS) Mineralys Therapeutics Posts Q2 Loss $2.85, vs. FactSet Est of $0.55 Loss - marketscreener.com
Mineralys Therapeutics earnings up next as losses expected to widen By Investing.com - Investing.com UK
Mineralys Therapeutics Appoints James J. Ferguson III as New Chief Medical Officer and Reports Q2 2026 Financial Results - Kalkine Media
Mineralys Therapeutics falls 8% on second quarter EPS miss By Investing.com - Investing.com Australia
Mineralys Therapeutics falls 8% on second quarter EPS miss - Investing.com India
Mineralys Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.00%
3.22%
자본화:
|
볼륨(24시간):